Cannabis Concentrates
International Growth Strategy
First Move: Australia
MediPharm Labs is in active conversations regarding the importing and exporting of
medical cannabis where federally permissible.
MediPharm Labs Australia Pty. Ltd. is MediPharm Labs' majority owned (80%)
subsidiary. Land has been purchased and construction is underway at the
MediPharm Labs Australia facility, the first step in the Company's international
growth strategy.
A manufacturing licence application is currently being reviewed by the Australian
Office of Drug Control. Facility is anticipated to be operational in Spring 2019
pending licensing.
The facility in Australia is designed to produce the same pharmaceutical grade
cannabis oil as MediPharm Labs' purpose-built facility in Barrie, Ontario.
Management expects the site, which is 1 hour south-east of Melbourne, to act as an
import and export hub, subject to licensing, until such time as Australian domestic-
patient-demand warrants dedicated production activities.
Corporate
Organizational Chart
MEDIPHARM LABS CORP. (ON)
PUBLICLY TRADED COMPANY
MEDIPHARM LABS INC. (ON)
LICENSED COMPANY
100%
100%
MPL PROPERTY
HOLDINGS INC.
(ON)
HOLDING PROPERTY
80%
MEDIPHARM
LABS AUSTRALIA
PTY. LTD.
(AUSTRALIA)
TSX-V: LABS MediPharm Labs | 10View entire presentation